Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ravulizumab versus placebo in adult patients with proliferative lupus nephritis or IgA nephropathy
NL-OMON54071Phase 2Recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ravulizumab in lupus nephritis (LN) and IgA nephropathy (IgAN), sponsored by Alexion Pharmaceuticals. Started Jan 2022; status: recruiting.
02
Drugs
ravulizumab
03
Conditions
lupus nephritis (LN)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NL-OMON54071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54071.